MedElevator
Войти в исследования Fundamental & clinical pharmacology · 2020
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lemaitre Florian, Solas Caroline, Grégoire Matthieu, Lagarce Laurence, Elens Laure, Polard Elisabeth, Saint-Salvi Béatrice, Sommet Agnès, Tod Michel, Barin-Le Guellec Chantal, French Society of Pharmacology, Therapeutics (SFPT), the International Association of Therapeutic Drug Monitoring, Clinical Toxicology (IATDMCT)
Аннотация
Patients with COVID-19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions. Here, we analyzed the potential or proven risk of the co-administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID-19. Practical recommendations are offered, where possible.
Предметные рубрики MeSH
AnalgesicsAnti-Asthmatic AgentsAnti-Bacterial AgentsAnti-Inflammatory AgentsAnticoagulantsAntineoplastic AgentsAntitubercular AgentsAntiviral AgentsBetacoronavirusCOVID-19Cardiovascular AgentsCoronavirus InfectionsDrug InteractionsHumansHydroxychloroquineHypoglycemic AgentsHypolipidemic AgentsInterferon beta-1bPandemicsPneumonia, ViralPrescription DrugsPsychotropic DrugsReceptors, InterleukinRisk AssessmentSARS-CoV-2Thyroid HormonesCOVID-19 Drug Treatment